We are live on ! Find out more
SYRE icon

Spyre Therapeutics
SYRE

64 hedge funds and large institutions have $155M invested in Spyre Therapeutics in 2018 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 22 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 4

433% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 6

85% more capital invested

Capital invested by funds: $84.1M → $155M (+$71.3M)

68% more funds holding

Funds holding: 38 → 64 (+26)

0.66% more ownership

Funds ownership: 2.03% → 2.69% (+0.66%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
64
Holders Change
+26
Holders Change %
+68.42%
% of All Funds
1.46%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
32
Increased
22
Reduced
4
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$7.85M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$6.31M
3
SFM
Sphera Funds Management
Israel
+$5.01M
4
Renaissance Technologies
Renaissance Technologies
New York
+$4.2M
5
Millennium Management
Millennium Management
New York
+$3.96M

Top Sellers

Rank Fund Capital Flow
1
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
-$1.81M
2
DZ Bank
DZ Bank
Germany
-$649K
3
SIM
Spark Investment Management
New York
-$188K
4
ARTA
A.R.T. Advisors
New York
-$183K
5
PAM
Panagora Asset Management
Massachusetts
-$158K
Name Holding Trade Value Shares
Change 		Change in
Stake
Acadian Asset Management
26
Acadian Asset Management
Massachusetts
$773K +$416K +1,690 +137%
EI
27
EAM Investors
California
$600K – – –
Wells Fargo
28
Wells Fargo
California
$552K +$245K +997 +91%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$438K +$407K +1,656 New
Morgan Stanley
30
Morgan Stanley
New York
$427K +$324K +1,315 +443%
Invesco
31
Invesco
Georgia
$382K +$355K +1,443 New
SLG
32
Stanley-Laman Group
Pennsylvania
$371K +$227K +923 +193%
Squarepoint
33
Squarepoint
New York
$350K +$221K +900 +212%
Charles Schwab
34
Charles Schwab
California
$321K +$298K +1,212 New
William Blair & Company
35
William Blair & Company
Illinois
$288K – – –
PA
36
Perceptive Advisors
New York
$272K +$253K +1,028 New
TCIM
37
TIAA CREF Investment Management
New York
$265K +$246K +1,000 New
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$264K +$246K +998 New
EMG
39
Ellington Management Group
Connecticut
$262K +$244K +992 New
LF
40
Lee Financial
Texas
$237K – – –
TA
41
Teachers Advisors
New York
$226K +$210K +853 New
AQR Capital Management
42
AQR Capital Management
Connecticut
$211K +$196K +797 New
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$191K +$178K +724 New
Goldman Sachs
44
Goldman Sachs
New York
$181K +$51.7K +210 +44%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$161K +$150K +609 New
Manulife (Manufacturers Life Insurance)
46
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$145K +$135K +550 New
Jacobs Levy Equity Management
47
Jacobs Levy Equity Management
New Jersey
$142K +$132K +535 New
CSS
48
Cubist Systematic Strategies
Connecticut
$131K +$122K +494 New
Two Sigma Investments
49
Two Sigma Investments
New York
$127K +$118K +481 New
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$124K +$113K +461 +5,763%
1
2
3

SYRE Hedge Fund Activity: Q2 2018 in Review

64 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2018, worth a combined $155M — up 85% from $84.1M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new SYRE positions and 6 closed out — a net gain of 26 holders — while 22 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, adding an estimated $7.85M. The largest seller was University of Texas/Texas AM Investment Management Co (UTIMCO), cutting an estimated $1.81M.

  • 64 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2018, up from 38 in Q1 2018.
  • Funds reported $155M of Spyre Therapeutics stock for Q2 2018, up 85% quarter-over-quarter.
  • 32 funds opened new Spyre Therapeutics positions in Q2 2018 and 6 closed out, a net change of +26 holders.
  • The largest Spyre Therapeutics buyer in Q2 2018 was BlackRock, an estimated $7.85M added.
  • The largest Spyre Therapeutics seller in Q2 2018 was University of Texas/Texas AM Investment Management Co (UTIMCO), an estimated $1.81M sold.

Based on aggregated 13F filings for Q2 2018.